K. R. Reddy

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Dieter Häussinger, Coleman Smith, oseph, 2002, The New England journal of medicine.

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

P. Thuluvath, D. Grasela, M. Sulkowski, 2014, The New England journal of medicine.

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials

K. Reddy, S. Klopfer, P. Kwo, 2020, Journal of viral hepatitis.

High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar

K. Reddy, K. Win, B. Loza, 2019, Journal of viral hepatitis.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

K. Reddy, T. Hassanein, D. Dieterich, 2013, The Lancet. Infectious diseases.

Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity

Tara L. Kieffer, S. Flamm, R. Demasi, 2015, Journal of clinical gastroenterology.

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis

E. Lawitz, N. Ravendhran, S. Flamm, 2023, Viruses.

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

T. Asselah, P. Marcellin, K. Reddy, 2015, The Lancet.